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Treatment of primary infected aortic aneurysm
without aortic resection
Sheng-Yueh Yu, MD,a Chun-Hui Lee, MD,b Hung-Chang Hsieh, MD,a An-Hsun Chou, MD,b and
Po-Jen Ko, MD,a Taoyuan, Taiwan, Province of China
Background:We sought to determine the safety and efficacy of two different treatment strategies for patients with primary
infected aortic aneurysms, including antibiotic treatment alone and endovascular aneurysm repair (EVAR) with
aggressive antibiotic treatment, as alternatives to the established treatment of open surgical repair.
Methods: We conducted a retrospective chart review of patients who were treated for infected aortic aneurysm without
undergoing aortic resection from January 2000 to December 2010 at a single institution.
Results: A total of 40 patients underwent traditional open repair during the study period. Sixteen patients with infected
aortic aneurysm (11 men; median age, 70; range, 44-80 years) were identified as not having undergone aortic resection
during the 11 years reviewed in the study. Nine patients received antibiotic treatment only (group I) and seven patients
underwent EVAR with aggressive antibiotic treatment (group II). Salmonella species were isolated from seven patients
in group I, and oxacillin-resistant Staphylococcus aureus was isolated from the remaining two patients. In group II, six
patients had blood culture results showing Salmonella species and one patient had a blood culture result showing
Escherichia coli. Group I (7 of 9 patients; 78%) had a higher hospital mortality rate than group II (0%; P  .003). Mean
follow-up among survivors was 10  15 months (range, 1-37 months). One patient in group II developed a reinfection
episode (14%). There was no significant difference between group I (67%; SE, 27.2%) and group II (86%; SE, 13.2%) in
the 3-month survival rates (log-rank, P  .39).
Conclusions: Our results support the premise that EVAR is beneficial for the patients with infected aortic aneurysm.
Treating an infected aortic aneurysm with antibiotics alone could not stop aneurysm expansion and eradicate the aortic
infection before the aneurysm ruptures. For the patients with infected aortic aneurysms who have limited life expectancy
and multiple comorbidities, EVAR with aggressive antibiotic treatment should be considered preferentially over
antibiotic treatment alone. (J Vasc Surg 2012;56:943-50.)
e
c
r
w
s
r
o
a
t
I
s
c
o
o
i
s
t
t
w
e
M
C
D
rInfected aortic aneurysms are rare and more difficult to
treat than simple atherosclerotic aneurysms. Conventional
treatment strategies include prolonged antibiotic therapy
and open surgical repair.1-3 Patients with infected aneu-
rysms are usually elderly, immunocompromised, and have
sepsis.2-4 With the great advances in medical care, surgery,
and postoperative care, the outcomes for traditional open
surgical repair have improved in the last 2 decades.5,6
However, these patients may have multiple comorbidities
and/or limited life expectancy, and the risk of traditional
open surgical repair may be prohibitive. Additionally, some
patients may be affected by a friend or relative who suffered
a poor outcome as a result of open aortic surgery, and they
therefore refuse conventional treatment strategies. For the
past 50 years, these patients have been managed with
various therapies, including supportive treatment, antibi-
otic treatment, and drainage of the abscess.7-9
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http://dx.doi.org/10.1016/j.jvs.2012.03.018Aortic surgery has evolved over the past 2 decades;
ndovascular surgery was developed for patients who were
onsidered to be physically ineligible for open surgical
epair. After endovascular aneurysm repair (EVAR) was
ell established in atherosclerotic aortic aneurysm,10 many
urgeons have applied EVAR for infected aortic aneurysm
epair as an alternative treatment or bridge procedure to
pen repair.10-14
EVAR was introduced to our hospital in 2004; we
pplied this minimally invasive technique to treat two pa-
ients with infected aortic aneurysms from 2006 to 2007.
n our previously reported study, these two patients had
atisfactory midterm results without further adjuvant pro-
edures or definite open repair.15 Herein, we have reviewed
ur experience in treating infected aortic aneurysms with-
ut aortic resection between 2000 and 2010. This series
ncludes our one previously reported EVAR case. We
ought to determine the safety and efficacy of two different
reatment strategies for patients who desired less invasive
reatments, including antibiotic treatment alone and EVAR
ith aggressive antibiotic treatment, as alternatives to the
stablished treatment of open surgical repair.
ETHODS
All patients were treated for infected aortic aneurysm at
hang Gung Memorial Hospital between January 2000 and
ecember 2010. Demographic data, clinical presentations,
esults of microbiologic cultures, aneurysm characteristics,
ntibiotics strategy, treatment method, complications, and
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October 2012944 Yu et alclinical outcomes were collected from medical records. Pa-
tients with prosthetic aortic graft infections were excluded.
The diagnosis of infected aortic aneurysm was established
based on a combination of clinical symptoms and signs of
infection, results of laboratory tests (white blood cell count
and C-reactive protein levels), positive results of blood cul-
tures, and typical imaging study findings (saccular aneurysm,
para-aortic soft tissue infiltration, and abnormal fluid accumu-
lation or gas formation around the aneurysm; Fig 1).
Once the diagnosis of primary infected aortic aneurysm
was confirmed, intravenous broad-spectrum antibiotics
were administrated empirically and infectious disease spe-
cialists were consulted. A specific antibiotic was determined
after culture results and sensitivity reports were available.
In the patients treated with EVAR, intervention was
performed after the fever subsided and white blood cell
counts and C-reactive protein levels declined, except if the
patient had a free ruptured aneurysm. All patients received
intravenous antibiotic therapy for at least 6 weeks or until
their body temperature, white blood cell count, and C-
reactive protein levels normalized. After discharge from the
hospital, oral antibiotic therapy was continued and guided
by the culture results for life.
Regular follow-ups were carried out for survivors. All
patients were re-accessed with clinical examinations and
laboratory tests (white blood cell count and C-reactive
protein levels) at our outpatient department. In patients
with antibiotic treatment alone, computed tomography
(CT) with intravenous contrast was repeated when the
patients presented with clinical evidence of reinfection (fe-
ver, localized pain, leukocytosis, and elevated C-reactive
protein levels). In patients treated with EVAR, imaging
studies (CT, lumbar spine four views) were repeated at 1, 6,
and 12 months and then annually thereafter, and when
patients presented with clinical evidence of reinfection.
Data were compiled and analyzed using SPSS 15.0
software (SPSS, Chicago, Ill). Means were compared using
a t-test; P values less than .05 were considered significant.
The Kaplan-Meier survival curves were generated for each
group. The log-rank test was conducted to examine if there
were any significant differences in survival among groups I
Fig 1. Typical image findings of primary infected aortic
accumulation (arrowhead). (B) Para-aortic gas formationand II. dESULTS
During the 11-year interval, 40 patients underwent
raditional open repair and 16 patients with infected aortic
neurysms that did not undergo aortic resection (11 men
nd five women) were identified. The patient demographics
re presented in the Table. A total of nine patients only
eceived medical treatment without further intervention
group I). Seven patients received medical treatment and
nderwent EVAR (group II). Patient #10 received medical
reatment alone initially and had rapid enlargement of an
nfected aortic aneurysm which was discovered with a CT
can during a follow-up visit. He underwent a late hybrid
VAR and visceral debranching (Fig 2).
The median age of the patients was 70 years (range,
4-80 years). The underlying diseases included hyperten-
ion in 10 patients, diabetes mellitus in seven patients,
ongestive heart failure in four patients, chronic obstructive
ulmonary disease in four patients, cerebrovascular acci-
ent in four patients, liver cirrhosis in three patients, end-
tage renal disease with regular hemodialysis in two pa-
ients, and coronary artery disease in two patients.
One patient had an infected thoracic aortic aneurysm,
ne patient had an infected suprarenal abdominal aortic
neurysm, and the remaining seven patients had infected
nfrarenal abdominal aortic aneurysms in group I. Whereas
wo patients had infected thoracic aortic aneurysms, one
atient had an infected pararenal abdominal aortic aneu-
ysm, and the remaining four patients had infected infrare-
al abdominal aortic aneurysms in group II. Salmonellawas
he leading pathogen (13 of 16; 81%) in this series, fol-
owed by Staphylococcus aureus (2 of 16; 13%). Salmonella
pecies were isolated from seven patients in group I, and
xacillin-resistant Staphylococcus aureus was isolated from
he remaining two patients. In group II, six patients had
ositive blood culture results showing Salmonella species
nd only one patient had an infected aortic aneurysm
aused by Escherichia coli. In group II, the patients had a
edian interval between diagnosis and endovascular repair
f 14 days, with a mean interval of 29 days (range, 0-127
ysm. (A) Saccular aneurysm (arrow) and abnormal fluid
owhead).aneurays). Patient #15 had a free ruptured infected aortic
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Volume 56, Number 4 Yu et al 945Table. Demographic data, findings, and clinical outcomes of patients with primary infected aortic aneurysms without
aortic resection
Patient No. Gender Age Underlying diseases Presentation Location Image findings
Group I
1 M 78 CHF, COPD,
GERD
Fever Suprarenal AA Aortic aneurysm involving
SMA root, IVC
thrombosis
2 F 74 DM, ESRD Fever, localized pain Infrarenal AA Pseudoaneurysm,
periaortic soft tissue
infiltration
3 M 63 CAD, CHF, COPD,
liver cirrhosis
Fever Infrarenal AA Periaortic soft tissue
infiltration
4 M 79 COPD, liver cirrhosis Fever, localized pain,
pulsatile mass, shock
Infrarenal AA pseudoaneurysm,
periaortic soft tissue
infiltration
5 M 77 DM, GERD, chronic
renal disease
Fever, localized pain Infrarenal AA Periaortic soft tissue
infiltration
6 M 75 Chronic lymphocytic
leukemia
Fever, shock Infrarenal AA Abnormal fluid
accumulation
7 F 60 DM, HTN, ESRD,
CVA, PAD
Fever, conscious disturbance Infrarenal AA Periaortic soft tissue
infiltration
8 F 80 HTN, GERD,
uterine
malignancy,
polymyositis
Localized pain, diarrhea Descending TA Periaortic soft tissue
infiltration
9 M 77 HTN,
hyperlipidemia,
gout
Fever, shock Infrarenal AA Periaortic soft tissue
infiltration
Group II
10 M 44 DM, HTN, CAD,
hyperlipidemia,
CVA
Fever, localized pain Pararenal AA Pseudoaneurysm,
periaortic soft tissue
infiltration
11 F 70 DM, HTN, gout Fever, localized pain,
hemoptysis
Descending TA Periaortic soft tissue
infiltration & gas
formation
12 M 75 HTN, CHF Localized pain Infrarenal AA Periaortic soft tissue
infiltration, abnormal
fluid accumulation
13 M 76 DM, HTN, CVA,
PAD
Fever, localized pain Infrarenal AA Pseudoaneurysm,
periaortic soft tissue
infiltration
14 F 74 DM, HTN, CHF,
CVA
Fever, localized pain Descending TA Pseudoaneurysm,
periaortic soft tissue
infiltration
15 M 52 Liver cirrhosis Localized pain Infrarenal AA Pseudoaneurysm,
ruptured
16 M 66 HTN, COPD
hyperlipidemia,
gout
Fever, localized pain Infrarenal AA Periaortic soft tissue
infiltration
Patient No. Pathogen
Preoperative
Tx, day Devices used Adjuvant procedure Hospital outcome Follow-up, month Late outcome
Group I
1 Salmonella . . . . . . . . . Dead (sepsis, DIC) . . . . . .
2 ORSA . . . . . . . . . Dead (aneurysm rupture) . . . . . .
3 Salmonella . . . . . . . . . Dead (cerebral infarction) . . . . . .
4 Salmonella . . . . . . . . . Dead (aneurysm rupture) . . . . . .
5 ORSA . . . . . . . . . Dead (aneurysm rupture) . . . . . .
6 Salmonella . . . . . . . . . Dead (aneurysm rupture) . . . . . .
7 Salmonella . . . . . . . . . Alive 1 Survival
8 Salmonella . . . . . . . . . Dead (sepsis) . . . . . .
9 Salmonella . . . . . . . . . Alive 37 Survival
AA, Abdominal aorta; Ax-Ax, axillo-axillary; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease;
CVA, cerebrovascular accident; DIC, disseminated intravascular coagulation; DM, diabetes mellitus; E, emergent operation; ESRD, end-stage renal disease;
GERD, gastroesophageal reflux disease; HTN, hypertension; IVC, inferior vena cava; ORSA, oxacillin-resistant Staphylococcus aureus; PAD, peripheral artery
disease; SMA, superior mesentery artery; TA, thoracic aorta; Tx, treatment.
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ative antibiotic treatment.
In group II, two patients underwent adjuvant procedures.
Patient #10 underwent visceral arteries (bilateral renal arteries
and superior mesentery artery) revascularization with bypass
Fig 2. Patient #10 had a pararenal infected aortic an
treatment was successful initially. (B) A rapid enlargeme
computed tomography (CT) scans 1 month after dischar
Table. Continued.
Patient No. Pathogen
Preoperative
Tx, day Devices used Adjuvant p
Group II
10 Salmonella 127 Iliac device Visceral debr
11 Salmonella 6 Thoracic Ax-Ax bypas
12 Escherichia
coli
7 Iliac device . . .
13 Salmonella 14 Iliac device . . .
14 Salmonella 21 Thoracic . . .
15 Salmonella E Bifurcated . . .
16 Salmonella 28 Bifurcated . . .debranching, rerouting, and endovascular grafting).raft (Fig 2, C and D). Another patient developed left hand
yanosis after thoracic EVAR. We performed axillo-axillary
ypass with an 8-mm expanded polytetrafluoroethylene pros-
hetic graft as an additional procedure for left subclavian artery
evascularization.
sm. (A) He received antibiotic treatment alone; and
the infected aortic aneurysm was detected in follow-up
andD)He underwent a late hybrid operation (visceral
re Hospital outcome Follow-up, month Late outcome
ng Alive 34 Survival
Alive 33 Survival
Alive 35 Survival
Alive 3 Survival
Alive 4 Survival
Alive 13 Survival
Alive 7 Survivaleury
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Volume 56, Number 4 Yu et al 947In-hospital outcome. The mean hospital stay was
44 28 days (range, 3-120 days). There was no significant
difference between the 30-day mortality rates of group I (4
of 9; 44%) than in group II (0%; P .088), whereas group
I (7 of 9; 78%) also had a higher hospital mortality rate than
group II (0%; P  .003). Aneurysm rupture (4 of 7; 57%)
was the leading cause of mortality in the hospital and sepsis
(2 of 7; 29%) was the second major cause of in-hospital
mortality. One patient died of a septic emboli-related
stroke. In group I, three of nine aneurysms ruptured and
caused mortality within 30 days. In group II, one patient
(patient #10) developed acute pulmonary edema after the
operation and required temporary ventilator support. After
using diuretics, he was successfully weaned from the venti-
lator 3 days later and recovered with no further events.
Follow-up outcome. Mean follow-up among survi-
vors was 10  15 months (range, 1-37 months). One
survivor of group I and two survivors of group II were
followed6months. Patient #15 had a reinfection episode
which presented with fever and localized pain. There was
no evidence of stent graft infection on follow-up CT scans,
but bilateral psoas abscesses were demonstrated (Fig 3). He
received an additional course of broad-spectrum intrave-
nous antibiotic therapy only and recovered with no further
events. All other group II patients recovered without rein-
fection episodes, secondary procedures, or conversion re-
quirements during the follow-up period (Fig 4). Kaplan-
Meier cumulative survival curves for cumulative survival
rates of patients are shown in Fig 5. There was no significant
difference between group I (67%; SE, 27.2%) and group II
(86%; SE, 13.2%) in the 3-month survival rates (log-rank,
P  .39).
DISCUSSION
Infected aortic aneurysm is a rare and potentially lethal
disease. In the literature, early diagnosis, prolonged antibi-
otic treatment, extensive debridement, and aneurysm re-
section followed by revascularization are the keys to suc-
cessful treatment of infected aortic aneurysm.However, the
surgical mortality rate was as high as 36% in the last cen-
tury,2,16 and some patients may not survive after aortic
clamping and revascularization. Therefore, conservative
treatment without infected aortic tissue resection became a
reasonable alternative treatment for these patients.
Although there have been advances in medical care and
antibiotic treatment, the prognosis of the group I patients
was not ideal. Aneurysm rupture followed by uncontrolled
exsanguination was still the leading cause of in-hospital
mortality in group I patients. It implied that antibiotic
treatment alone failed to stop infected aortic aneurysm
expansion and these patients died of aneurysm rupture
before the eradication of sepsis. Concerning the pathogen-
esis and evolution of infected aneurysms, the arterial wall is
usually damaged by the infection and irreversibly dilated.17
The damaged wall continues to sustain significant systemic
arterial pressure even if infection has been controlled or
eradicated. It may be the reason why one third of infected
aortic aneurysms in this series ruptured within 30 days after siagnosis, even with prompt antibiotic treatment. Aggres-
ive adjuvant therapy for the prevention of infected aneu-
ysm rupture is important.
EVAR was originally developed for patients who had
therosclerotic aortic aneurysms and were considered to be
hysically ineligible for open surgical repair,10 and was
ssociated with a significantly lower operative mortality
han traditional open surgical repair.18,19 In the last de-
ade, many authors looked to this minimally invasive pro-
edure as another alternative of temporizing treatment in
atients with infected aortic aneurysms.11,13,14,20-24 After
he stent graft excluded the damaged aortic wall from
ystemic arterial pressure, a catastrophic infected aortic
neurysm rupture was prevented. Previous researchers have
lso implied that EVAR conferred acceptable midterm sur-
ival rates for treating infected aortic aneurysm.11,14,25,26
However, several reports presented unfavorable out-
omes and suggested that survivors may need subsequent
pen repair during follow-up due to reinfection.27,28 The
ain controversy of the application of EVAR for infected
ortic aneurysm revolved around placing a stent graft in an
nfected field. Although the aneurysms are excluded by the
tent graft and aneurysm rupture is prevented, the contents
f the infected aneurysmal sac are responsible for sepsis, as
roven by the high incidence of positive tissue cultures
uring surgery in the era of open repair.2 Placement of a
oreign body in an infected bed goes against general surgi-
al principle and may cause persistent infection or reinfec-
ion.
Fever and aneurysm rupture at operation are the most
ig 3. Patient #15 had abdominal discomfort, lower back pain,
nd elevated C-reactive protein levels 1 month after discharge.
ollow-up computed tomography (CT) scans demonstrated rein-
ection with abscesses in the bilateral psoas muscles and no evi-
ence of stent graft infection. He received another course of
road-spectrum intravenous antibiotic therapy and recovered un-
ventfully. He is well after 13 months of follow-up.ignificant predictors associated with the occurrence of
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October 2012948 Yu et alpersistent infection in these patients.29 We applied EVAR
in these patients after infection was controlled, which man-
ifested with subsided fever and declined white blood cell
Infected
Medical treatment
N=10
Hospital death
N=7
Hospital survival
N=3
1-year survival
N=1
Medical treatment only
N=9
Survivors
follow-up < 1-year
N=1
Fig 4. Clinical outcomes of treating 16 patientswith infect
Endovascular aneurysm repair.
Fig 5. There was no significant difference between grou
3-month survival rates, which were calculated using the Ka
aneurysm repair.count and C-reactive protein levels, except in patient #15. without adequate preoperative antibiotic treatment, he
eveloped reinfection. After the infected aortic aneurysm
uptured, the pathogen spread to para-aortic soft tissue,
c aneurysm
6
EVAR
N=6
te hybrid operation
N=1
Surgical treatment without 
aortic resection
N=7
-year survival
N=4
Survivors
follow-up < 1-year
N=3
e-infection
N=1
No re-infection
N=6
rtic aneurysmwithout undergoing aortic resection.EVAR,
67%; SE, 27.2%) and group II (86%; SE, 13.2%) in the
Meier method (log-rank, P  .39). EVAR, Endovascular aorti
N=1
La
1
R
ed aop I (
plan-hich became the reinfection nidus. In the Clough et al11
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Volume 56, Number 4 Yu et al 949report, recurrences led to fatal outcomes. However, these
patients all developed aortic fistula before EVAR. Clough
et al11 suggested that EVAR was not able to address the
situation and the stent graft was subjected to a continuing
source of infection. Kritpracha et al12 also reported that
EVAR had a poor outcome in patients with fistula compli-
cation. In the experience of Sörelius et al,14 the recurrence-
related mortality rate was 33.3% (1 of 3). This patient, who
was taking immunosuppressive drugs, was at high risk for
succumbing to sepsis. Compared with said studies, patient
#15 did not have an aortic fistula before EVAR and was not
taking immunosuppressive drugs; therefore, the recurrence
could be controlled by antibiotic treatment.
However, challenging anatomy and an inadequate
landing zone limited the application of EVAR. In this
series, patient #10 needed vascular debranching and re-
routing before stenting. This type of hybrid EVAR avoided
aortic cross-clamping and decreased the risk of cardiac
complications. But hybrid operations are time-consuming
and present a risk of bypass graft complications such as renal
failure and bowel ischemia.28,30 Fenestrated and branched
endografts and EVAR with the chimney or snorkel proce-
dure are other alternatives. However, feasible chimney
stents and fenestrated and branched endografts were not
available at our hospital during the study period. According
to published reports, the patients with distal arch or para-
visceral aortic lesions might benefit from these alterna-
tives.31-33
Based on the clinical results of the group II patients,
EVAR provided a lower in-hospital mortality rate. It pro-
vided more time for sepsis control or eradication by the
antibiotic treatment. EVAR prevented the expansion and
rupture of the infected aortic aneurysm, which was the
leading cause of mortality for group I patients during
antibiotic treatment.
Study limitations. The retrospective nature of the
study, including retrospective data collection, and a small
study sample were important limitations of this study.
Another limitation was the selection bias between groups I
and II. The bias in selection was based on cost and life
expectancy. Furthermore, follow-up time was limited. One
third of the survivors were followed up for6months. The
potential risk of complication has not been ruled out.
Further studies with larger populations and longer fol-
low-up periods are warranted to determine the durability of
EVAR in treating infected aortic aneurysms.
CONCLUSIONS
Although limitations exist, our experience showed that
EVAR had benefits for patients with infected aortic aneu-
rysm. The results support the premise that EVAR has
benefitted patients with infected aortic aneurysm. It results
in lower in-hospital mortality rates and has acceptable
short-term survival outcomes. Treating infected aortic an-
eurysm with antibiotics alone could not stop aneurysm
expansion and eradicate the aortic infection before the
aneurysm ruptured. EVAR prevents the catastrophe of
aneurysm rupture before the eradication of sepsis. Foratients with infected aortic aneurysm who have limited life
xpectancy andmultiple comorbidities, EVARwith aggres-
ive antibiotic therapy should be considered preferentially
ver antibiotic treatment alone. The duration of antibiotic
herapy, the timing of intervention, and long-term out-
omes are important issues and require further investiga-
ions and more follow-up data from studies with larger
ample populations.
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